Advocacy intelligence hub — real-time data for patient organizations
OBIZUR: FDA approved
Treatment of bleeding episodes in adults with acquired hemophilia A.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
OBIZUR
Takeda Development Center Americas, Inc.
OBIZUR
(antihemophilic factor (recombinant), porcine sequence)Orphan drugTakeda Development Center Americas, Inc.
Browse all Rare thrombotic disorder due to a coagulation factors defect news →
View all Rare thrombotic disorder due to a coagulation factors defect specialists →